Background: We previously showed that the mTOR pathway is activated in castrate resistant
prostate cancer (CRPC) while inhibition of this pathway upregulated androgen receptor (AR) …

157 Background: Multiple signaling pathways are involved in the development of CRPC. We
previously showed that the mTOR pathway is activated in CRPC cell lines while inhibition of …

e15131 Background: Multiple signaling pathways are involved in the development of CRPC.
We previously showed that the mTOR pathway is activated in CRPC cell lines while …

5028 Background: We previously reported that the mammalian target of rapamycin (mTOR)
pathway was upregulated in CRPC, and that inhibition of mTOR was ineffective in killing …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Purpose: Androgen receptor (AR) inhibition can upregulate c-MET expression, which may
be a resistance mechanism driving progression of castration-resistant prostate cancer …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …

Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …

Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

5066 Safety and efficacy of Everolimus (E), bevacizumab (B), and docetaxel (D) for
castration resistant prostate cancer (CRPC) Background: Based on studies suggesting co …